Agios Pharmaceuticals Inc. (AGIO) Moves Lower on Volume Spike for December 05

Equities Staff  |

Agios Pharmaceuticals Inc. (AGIO) traded on unusually high volume on Dec. 05, as the stock lost 12.45% to close at $49.88. On the day, Agios Pharmaceuticals Inc. saw 3.54 million shares trade hands on 28,377 trades. Considering that the stock averages only a daily volume of 618,781 shares a day over the last month, this represents a pretty significant bump in volume over the norm.

Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.

The stock has traded between $67.98 and $33.50 over the last 52-weeks, its 50-day SMA is now $54.92, and its 200-day SMA $47.54. Agios Pharmaceuticals Inc. has a P/B ratio of 5.22.

Agios Pharmaceuticals Inc is engaged in the development of medicines to treat cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.

Headquartered in Cambridge, MA, Agios Pharmaceuticals Inc. has 208 employees and is currently under the leadership of CEO David P. Schenkein.

For a complete fundamental analysis analysis of Agios Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for AGIO.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.

To get more information on Agios Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: AGIO’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: